Literature DB >> 16344053

Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD.

Séverine Vermeire1, Marie Pierik, Tibor Hlavaty, Greet Claessens, Nele van Schuerbeeck, Sofie Joossens, Marc Ferrante, Liesbet Henckaerts, Mirjam Bueno de Mesquita, Robert Vlietinck, Paul Rutgeerts.   

Abstract

BACKGROUND & AIMS: Three years after the identification of NOD2/CARD15, 2 more genes for inflammatory bowel diseases (IBDs) were reported. The carnitine/organic cation transporter (OCTN) on 5q31 (IBD5) is associated with Crohn's disease (CD) and DLG5 (10q23), a member of membrane-associated guanylate kinase (MAGUK) family, with IBD. We studied mutation prevalence, assessed phenotypic expression, and performed conditional analysis to examine evidence for gene-gene interactions.
METHODS: A cohort of 2032 individuals was genotyped for disease-associated OCTN and DLG5 variants, including 981 patients with IBD (CD, n = 769; ulcerative colitis, n = 186; indeterminate colitis, n = 26) followed up at a tertiary IBD center. For 373 patients, DNA from both parents was available (cohort 1) for transmission disequilibrium testing analysis; case-control analysis was performed in 608 patients and 305 controls (cohort 2).
RESULTS: There was no distortion of transmission toward affected offspring for any of the variant alleles. Case-control analysis also failed to shown an association. A higher frequency of DLG5 113A was observed in CARD15-positive patients (12.2%) compared with CARD15-negative patients (8.7%; P = .033). The OCTN-TC risk haplotype was associated with penetrating disease (odds ratio, 1.474; 95% confidence interval, 1.028-2.114; P = .035). For DLG5, there were no associations with a particular phenotype.
CONCLUSIONS: DLG5 and OCTN do not play a role in the susceptibility to IBD, CD, or ulcerative colitis in the Flemish population but play a role in the phenotypic expression of the disease. OCTN variants were associated with perianal and penetrating CD. More studies in independent populations are urgently needed to assess the validity of DLG5 and OCTN in the pathogenesis of IBD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344053     DOI: 10.1053/j.gastro.2005.10.006

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  33 in total

1.  Contribution of the IBD5 locus to inflammatory bowel disease: a meta-analysis.

Authors:  Jian Wang; Xi Wang; Hong Yang; Dong Wu; Li Wang; Jiaming Qian
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

Review 2.  Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut?

Authors:  Zili Zhang; James T Rosenbaum; Wenwei Zhong; Carmen Lim; David J Hinrichs
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

3.  Cytokine regulation of OCTN2 expression and activity in small and large intestine.

Authors:  Mikihiro Fujiya; Yuhei Inaba; Mark W Musch; Shien Hu; Yutaka Kohgo; Eugene B Chang
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

4.  IBD5 is associated with an extensive complicated Crohn's disease feature: implications from genotype-phenotype analysis.

Authors:  S Brescianini; T Trinh; M Stoll; S Schreiber; J D Rioux; M J Daly
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

Review 5.  Genetics of inflammatory bowel disease: current status and future directions.

Authors:  Thomas D Walters; Mark S Silverberg
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

6.  Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice.

Authors:  Prem S Shekhawat; Sonne R Srinivas; Dietrich Matern; Michael J Bennett; Richard Boriack; Varghese George; Hongyan Xu; Puttur D Prasad; Penny Roon; Vadivel Ganapathy
Journal:  Mol Genet Metab       Date:  2007-09-19       Impact factor: 4.797

7.  IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn's disease in Hungarian patients.

Authors:  Lilla Lakner; Veronika Csöngei; Patrícia Sarlós; Luca Járomi; Eniko Sáfrány; Márta Varga; Péter Orosz; Lili Magyari; Judit Bene; Pál Miheller; Zsolt Tulassay; Béla Melegh
Journal:  Int J Colorectal Dis       Date:  2009-02-13       Impact factor: 2.571

8.  Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions.

Authors:  Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2008-11       Impact factor: 5.325

Review 9.  The future of molecular approaches to inflammatory bowel disease.

Authors:  Boyko Kabakchiev; Smita Halder; Mark S Silverberg
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  L-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation.

Authors:  G Fortin; K Yurchenko; C Collette; M Rubio; A-C Villani; A Bitton; M Sarfati; D Franchimont
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.